A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis

BACKGROUND: Antibiotics for the treatment of complicated, multidrug-resistant Gram-positive infections are limited, especially when prolonged treatment is necessary. Oritavancin is approved for the treatment of serious skin infections as a 1200 mg single-dose regimen, but case reports describe suppl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Warren E., Hutson, Paul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334312/
https://www.ncbi.nlm.nih.gov/pubmed/32588386
http://dx.doi.org/10.1007/s40801-020-00188-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334312/
https://www.ncbi.nlm.nih.gov/pubmed/32588386
http://dx.doi.org/10.1007/s40801-020-00188-6

Ejemplares similares